Visby Medical Launches At-Home STI PCR Test
- Here's a breakdown of the key information from the provided text, focusing on Visby Medical's at-home STI test:
- * Technology: A rapid, at-home diagnostic test using PCR technology.
- * Ease of Use: Designed to be simple - "close the lid and the test starts running." * Treatment Connection: Connects positive results to healthcare...
Here’s a breakdown of the key information from the provided text, focusing on Visby Medical’s at-home STI test:
What the Test Is:
* Diagnoses: Chlamydia, gonorrhea, and trichomoniasis.
* Technology: A rapid, at-home diagnostic test using PCR technology. It doesn’t require sending a sample to a lab.
* Speed: Results in 30 minutes.
* Accuracy: High accuracy rates demonstrated in trials:
* Chlamydia: 98.8% negative, 97.2% positive
* gonorrhea: 99.1% negative, 100% positive
* Trichomoniasis: 98.5% negative, 97.8% positive
* FDA cleared: First at-home diagnostic for these STIs, cleared in March.
* Price: $149.99
How it effectively works & Access:
* Ease of Use: Designed to be simple – “close the lid and the test starts running.”
* Treatment Connection: Connects positive results to healthcare providers via United Healthcare’s optumnow telehealth service.
* Delivery: Available for same-day delivery in 10 major cities (Las Vegas, Atlanta, New York, San Francisco, Seattle, etc.) through GoPuff and DoorDash. Also available via the Visby website.
* Partnership: Sold through everlywell.
Company Information (Visby Medical):
* founded: 2012
* Funding: Has raised a total of $486 million.
* $55 million in July (led by Catalio Capital Management)
* $135 million in 2022 (valued the company at over $1 billion)
* History: Initially focused on at-home PCR testing, pivoted to COVID-19 testing during the pandemic, but always aimed to return to STI testing.
Key Differentiator:
* True Diagnostic vs. screening: Visby’s test is a diagnostic test, meaning it provides a definitive diagnosis, unlike some at-home screenings that require lab confirmation. This allowed them to integrate treatment access into the process.